Skip to main content

Table 18 (abstract P23). Patient reported outcomes

From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

Outcome measures

Mean change from baseline (n/N)a,c

crFMF

HIDS/MKD

TRAPS

Week 5

Week 16

Week 5

Week 16

Week 5

Week 16

SF-12 PCS

7.9 (29/30)

9.55 (30/31)

13.81 (15/15)

13.81 (14/14)

9.63 (16/17)

11.64 (13/14)

SF-12 MCS

4.83 (29/30)

4.27 (30/31)

6.41 (15/15)

8.14 (14/14)

5.65 (16/17)

5.51 (13/14)

CHQ-PF50 PhS

13.2 (21/24)

20.1 (18/21)

5.5 (32/34)

9.9 (27/29)

7.4 (16/18)

14.9 (13/14)

CHQ-PF50 PsS

4.1 (21/24)

7.2 (18/21)

1.8b (32/34)

5.2 (27/29)

0.9b (16/18)

1.2b (13/14)

  1. N total number of pts, n pts who received at least one dose of CAN
  2. aAn increase in mean score from baseline is an improvement
  3. bMinimal important difference [1,2] from baseline was not achieved
  4. cIn the general U.S. population, mean summary scores are 50 for CHQ-PF50 and 50 for SF-12 (50.01 and 49.98, respectively for PCS and MCS). [3,4]
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096